MeSH tree: C04.557.337.428.080.125
"COVID is not pretty in a nursing home," said Deb Wityk, a 70-year-old retired massage therapist who lives in one called Spurgeon Manor, in rural Iowa. She twice contracted the disease and is eager to get the newly approved ...
Sep 28, 2023
0
39
Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published ...
Aug 17, 2023
0
139
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ...
Jul 14, 2023
0
94
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically ...
Jun 7, 2023
0
70
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
94
A new editorial paper titled " Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway" has been published in Oncotarget.
Apr 4, 2023
0
46
Next-generation sequencing studies have in recent years revealed numerous recurrently mutated genes in chronic lymphocytic leukemia (CLL). These mutations are usually found in a relatively small percentage of cases and associated ...
Mar 3, 2023
0
91
New adoptive T cell therapies—in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, and ...
Feb 10, 2023
0
124
The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jan 24, 2023
0
95
Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study published ...
Jan 3, 2023
0
67
